EBS vs. NVDA
Compare and contrast key facts about Emergent BioSolutions Inc. (EBS) and NVIDIA Corporation (NVDA).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: EBS or NVDA.
Correlation
The correlation between EBS and NVDA is 0.40, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
EBS vs. NVDA - Performance Comparison
Key characteristics
EBS:
0.24
NVDA:
0.53
EBS:
1.29
NVDA:
1.05
EBS:
1.17
NVDA:
1.13
EBS:
0.29
NVDA:
0.78
EBS:
0.68
NVDA:
1.94
EBS:
41.77%
NVDA:
14.87%
EBS:
124.84%
NVDA:
59.43%
EBS:
-98.89%
NVDA:
-89.73%
EBS:
-95.81%
NVDA:
-21.93%
Fundamentals
EBS:
$268.97M
NVDA:
$2.79T
EBS:
-$3.60
NVDA:
$2.94
EBS:
1.55
NVDA:
1.61
EBS:
0.26
NVDA:
21.28
EBS:
0.58
NVDA:
35.22
EBS:
$737.80M
NVDA:
$104.45B
EBS:
$181.00M
NVDA:
$77.45B
EBS:
-$26.50M
NVDA:
$68.38B
Returns By Period
In the year-to-date period, EBS achieves a -40.90% return, which is significantly lower than NVDA's -13.13% return. Over the past 10 years, EBS has underperformed NVDA with an annualized return of -14.49%, while NVDA has yielded a comparatively higher 72.66% annualized return.
EBS
-40.90%
20.47%
-52.00%
29.29%
-41.33%
-14.49%
NVDA
-13.13%
2.03%
-20.97%
31.47%
72.07%
72.66%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
EBS vs. NVDA — Risk-Adjusted Performance Rank
EBS
NVDA
EBS vs. NVDA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Emergent BioSolutions Inc. (EBS) and NVIDIA Corporation (NVDA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
EBS vs. NVDA - Dividend Comparison
EBS has not paid dividends to shareholders, while NVDA's dividend yield for the trailing twelve months is around 0.03%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EBS Emergent BioSolutions Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 5.65% | 0.00% | 0.00% |
NVDA NVIDIA Corporation | 0.03% | 0.02% | 0.03% | 0.11% | 0.05% | 0.12% | 0.27% | 0.46% | 0.29% | 0.45% | 1.20% | 1.70% |
Drawdowns
EBS vs. NVDA - Drawdown Comparison
The maximum EBS drawdown since its inception was -98.89%, which is greater than NVDA's maximum drawdown of -89.73%. Use the drawdown chart below to compare losses from any high point for EBS and NVDA. For additional features, visit the drawdowns tool.
Volatility
EBS vs. NVDA - Volatility Comparison
Emergent BioSolutions Inc. (EBS) has a higher volatility of 37.43% compared to NVIDIA Corporation (NVDA) at 14.66%. This indicates that EBS's price experiences larger fluctuations and is considered to be riskier than NVDA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
EBS vs. NVDA - Financials Comparison
This section allows you to compare key financial metrics between Emergent BioSolutions Inc. and NVIDIA Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
EBS vs. NVDA - Profitability Comparison
EBS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported a gross profit of 71.30M and revenue of 189.30M. Therefore, the gross margin over that period was 37.7%.
NVDA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, NVIDIA Corporation reported a gross profit of 28.72B and revenue of 39.33B. Therefore, the gross margin over that period was 73.0%.
EBS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported an operating income of -9.50M and revenue of 189.30M, resulting in an operating margin of -5.0%.
NVDA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, NVIDIA Corporation reported an operating income of 24.03B and revenue of 39.33B, resulting in an operating margin of 61.1%.
EBS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Emergent BioSolutions Inc. reported a net income of -31.30M and revenue of 189.30M, resulting in a net margin of -16.5%.
NVDA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, NVIDIA Corporation reported a net income of 22.09B and revenue of 39.33B, resulting in a net margin of 56.2%.